1. Grindey GB: Identification of Diarylsulfonylureas as novel anticancer drugs. Proc Am Assoc Cancer Res 29:535, 1988
2. Grindey GB, Boder GB, Grossman CS, Howbert JJ, Poore GA, Show WN, Todd GC, Worzalla JF. Further development of Diarylsulfonylureas as novel anticancer drugs. Proc Am Assoc Cancer Res 28:309, 1987
3. Houghton PJ, Houghton JA, Myers I, Cheshire P, Howbert JS, Grindey GB: Evaluation of N-(5-indanylsulfonyl)-N1-4 Chlorophenyl-urea against xenografts of pediatric rhabolomyosarcoma. Cancer Chemother Pharmacol 25:48?87, 1989
4. Armand JP, Recondo G, Gouyette A, Belerahdek M, Bonnay M, Chabot G, L'homme C: Phase I and pharmacokinetic study of LY 186641 administered daily for 2 weeks every 21 days. Inv New Drugs 7:423, 1989
5. Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, Saluron SE: Clinical pharmacology of a novel Diarylsulfonylurea anticancer agent. J Clin Oncol 7:1733?1740, 1989